-
-
-
-
-
-
-
FDA lifts partial clinical hold on MacroGenics' cancer drug study
-
-
-
-
-
-
-
Macrogenics (MGNX) Misses Q2 EPS by 11c, Misses on Revenue
-
-
-
-
-
-
-
MacroGenics (MGNX) PT Lowered to $2 at H.C. Wainwright
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Neutral Rating on MacroGenics (MGNX)
-
-
-
-
-
-
-
B.Riley Downgrades MacroGenics (MGNX) to Neutral
-
-
-
418,439 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

